论文部分内容阅读
许多研究表明，人和动物的血浆中存在一种内源性炎洋地黄因子（ＥＤＬＳ），具有很强的强心、利尿、利钠和缩血管作用〔１〕。苯那普利是新一代血管紧张素转换酶抑制剂，临床已用于治疗充血性心力衰竭（ＣＨＦ）。本文观察该药对ＣＨＦ患者血浆ＥＤＬＳ水平的影响，以探讨其治?
Many studies have shown that human and animal plasma exists in an endogenous inflammatory digitalis (EDLS), has a strong cardiac, diuretic, sodium and vasoconstrictive effects [1]. Benazepril is a new generation of angiotensin-converting enzyme inhibitors, which have been clinically used to treat congestive heart failure (CHF). This article observed the drug on the plasma levels of EDLS in CHF patients to explore its treatment?